Listen to The Lancet: 04 January
Gerd Burmester and Richard Lane discuss a potential new treatment for refractory rheumatoid arthritis. (Source: Listen to The Lancet)
Source: Listen to The Lancet - January 4, 2013 Category: Journals (General) Authors: The Lancet Source Type: podcasts
The Lancet: January 04, 2013
Gerd Burmester and Richard Lane discuss a potential new treatment for refractory rheumatoid arthritis. (Source: Listen to The Lancet)
Source: Listen to The Lancet - January 4, 2013 Category: Journals (General) Authors: The Lancet Source Type: podcasts
Rheumatoid Arthritis: New Class, New Approval, New Approach
A look at how the pharmacotherapeutic management of RA is evolving. (Source: Medscape Rheumatology Podcast)
Source: Medscape Rheumatology Podcast - November 29, 2012 Category: Rheumatology Authors: Medscape Source Type: podcasts
Tofacitinib Approved: Now How Do We Use It?
Dr. Jonathan Kay discusses the potential role of the recently approved oral kinase inhibitor tofacitinib for rheumatoid arthritis. (Source: Medscape Rheumatology Podcast)
Source: Medscape Rheumatology Podcast - November 28, 2012 Category: Rheumatology Authors: Medscape Source Type: podcasts
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Biologic Therapy: A Meta-analysis
Interview with Maria E Suarez-Almazor, MD, PhD, author of Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Biologic Therapy: A Meta-analysis (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - September 4, 2012 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA 2012-09-05, Vol. 308, No. 9, Author Interview
Interview with Maria E Suarez-Almazor, MD, PhD, author of Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Biologic Therapy: A Meta-analysis (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - September 4, 2012 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
A Welcome Oral for Rheumatoid Arthritis
Dr. Jonathan Kay discusses a new first-in-class agent for rheumatoid arthritis recently recommended for approval by an FDA advisory panel. (Source: Medscape Rheumatology Podcast)
Source: Medscape Rheumatology Podcast - July 6, 2012 Category: Rheumatology Authors: Medscape Source Type: podcasts
Say Guten Tag to 8 Important Rheumatoid Arthritis Studies
Dr. Jon Kay interviews Dr. Ronald van Vollenhoven on important rheumatoid arthritis data presented at EULAR 2012. (Source: Medscape Rheumatology Podcast)
Source: Medscape Rheumatology Podcast - June 20, 2012 Category: Rheumatology Authors: Medscape Source Type: podcasts
Arthritis, Fever, and Frontal Headache: Make the Diagnosis
Dr. Jonathan Kay discusses the case of a woman with juvenile rheumatoid arthritis and uveitis who developed headache and a fever. The diagnosis might surprise you. (Source: Medscape Rheumatology Podcast)
Source: Medscape Rheumatology Podcast - January 11, 2012 Category: Rheumatology Authors: Medscape Source Type: podcasts
JAMA: 2011-02-02, Vol. 305, No. 5, Author in the Room™ Audio Interview
Interview with Gabriela Schmajuk, MD, author of Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans. Summary Points: 1. One third of Medicare managed care patients diagnosed with rheumatoid arthritis are not receiving disease-modifying antirheumatic drugs. 2. There is variation in disease-modifying antirheumatic drug receipt based on "accidental factors": sociodemographics, geographic location, and health plan. 3. Because disease-modifying antirheumatic drug use is the main way to affect outcomes in rheumatoid arthritis, these patient groups and the physi...
Source: JAMA Author in the Room - March 18, 2011 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2011-02-02, Vol. 305, No. 5, Author in the Room ™ Audio Interview
Interview with Gabriela Schmajuk, MD, author of Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans. Summary Points: 1. One third of Medicare managed care patients diagnosed with rheumatoid arthritis are not receiving disease-modifying antirheumatic drugs. 2. There is variation in disease-modifying antirheumatic drug receipt based on "accidental factors": sociodemographics, geographic location, and health plan. 3. Because disease-modifying antirheumatic drug use is the main way to affect outcomes in rheumatoid arthritis, these patient groups and the physi...
Source: JAMA Author in the Room - March 18, 2011 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
